{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:36:53Z","timestamp":1781829413461,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"DOI":"10.7759\/cureus.79582","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T02:11:49Z","timestamp":1740449509000},"source":"Crossref","is-referenced-by-count":3,"title":["Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis\/Primary Biliary Cholangitis With Futuristic Treatments"],"prefix":"10.7759","author":[{"given":"Asad Ali","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furqan","family":"Ul Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qazi Muhammad Farooq","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeem","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.062","article-title":"Definition and management of patients with primary biliary cholangitis and an incomplete response to therapy","volume":"19","author":"Montano-Loza AJ","year":"2021","unstructured":"Montano-Loza AJ, Corpechot C. Definition and management of patients with primary biliary cholangitis and an incomplete response to therapy. Clin Gastroenterol Hepatol. 2021, 19:2241-51.e1. 10.1016\/j.cgh.2020.06.062","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield GM","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander GJ, et al.. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018, 67:1568-94. 10.1136\/gutjnl-2017-315259","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000440705","article-title":"Worldwide incidence of autoimmune liver disease","volume":"33 Suppl 2","author":"Jepsen P","year":"2015","unstructured":"Jepsen P, Gr\u00f8nb\u00e6k L, Vilstrup H. Worldwide incidence of autoimmune liver disease. Dig Dis. 2015, 33 Suppl 2:2-12. 10.1159\/000440705","journal-title":"Dig Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019, 69:394-419. 10.1002\/hep.30145","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV, Jacobson IM. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019, 114:48-63. 10.1038\/s41395-018-0390-3","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2023.07.004","article-title":"Systemic complications of primary biliary cholangitis","volume":"28","author":"Zapata M","year":"2024","unstructured":"Zapata M, Pagan-Torres H, Mayo MJ. Systemic complications of primary biliary cholangitis. Clin Liver Dis. 2024, 28:115-28. 10.1016\/j.cld.2023.07.004","journal-title":"Clin Liver Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13676","article-title":"Regarding: risk of fractures and postfracture mortality in 3980 people with primary biliary cholangitis","volume":"294","author":"Chang HC","year":"2023","unstructured":"Chang HC, Gau SY. Regarding: risk of fractures and postfracture mortality in 3980 people with primary biliary cholangitis. J Intern Med. 2023, 294:536. 10.1111\/joim.13676","journal-title":"J Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cld.901","article-title":"Managing the symptoms and complications of cholestasis","volume":"15","author":"Pedersen MR","year":"2020","unstructured":"Pedersen MR, Mayo MJ. Managing the symptoms and complications of cholestasis. Clin Liver Dis (Hoboken). 2020, 15:120-4. 10.1002\/cld.901","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-28032015000500002","article-title":"Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver","volume":"52 Suppl 1","author":"Bittencourt PL","year":"2015","unstructured":"Bittencourt PL, Can\u00e7ado EL, Couto CA, et al.. Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. Arq Gastroenterol. 2015, 52 Suppl 1:15-46. 10.1590\/S0004-28032015000500002","journal-title":"Arq Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5009\/gnl16365","article-title":"Extrahepatic manifestations of primary biliary cholangitis","volume":"11","author":"Chalifoux SL","year":"2017","unstructured":"Chalifoux SL, Konyn PG, Choi G, Saab S. Extrahepatic manifestations of primary biliary cholangitis. Gut Liver. 2017, 11:771-80. 10.5009\/gnl16365","journal-title":"Gut Liver"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101916","article-title":"Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis","volume":"9","author":"Hu SL","year":"2014","unstructured":"Hu SL, Zhao FR, Hu Q, Chen WX. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One. 2014, 9:e101916. 10.1371\/journal.pone.0101916","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2022.06.004","article-title":"Autoantibodies in primary biliary cholangitis","volume":"26","author":"Leung KK","year":"2022","unstructured":"Leung KK, Hirschfield GM. Autoantibodies in primary biliary cholangitis. Clin Liver Dis. 2022, 26:613-27. 10.1016\/j.cld.2022.06.004","journal-title":"Clin Liver Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07122-y","article-title":"Anti-mitochondrial antibody-negative primary biliary cholangitis is part of the same spectrum of classical primary biliary cholangitis","volume":"67","author":"Can\u00e7ado GG","year":"2022","unstructured":"Can\u00e7ado GG, Braga MH, Ferraz ML, et al.. Anti-mitochondrial antibody-negative primary biliary cholangitis is part of the same spectrum of classical primary biliary cholangitis. Dig Dis Sci. 2022, 67:3305-12. 10.1007\/s10620-021-07122-y","journal-title":"Dig Dis Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2018.03.014","article-title":"Chronic complications of cholestasis: evaluation and management","volume":"22","author":"Assis DN","year":"2018","unstructured":"Assis DN. Chronic complications of cholestasis: evaluation and management. Clin Liver Dis. 2018, 22:533-44. 10.1016\/j.cld.2018.03.014","journal-title":"Clin Liver Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist G","year":"2017","unstructured":"Dahlqvist G, Gaouar F, Carrat F, et al.. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 2017, 65:152-63. 10.1002\/hep.28859","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175713","article-title":"Risk stratification in primary biliary cholangitis","volume":"12","author":"Martini F","year":"2023","unstructured":"Martini F, Balducci D, Mancinelli M, et al.. Risk stratification in primary biliary cholangitis. J Clin Med. 2023, 12:5713. 10.3390\/jcm12175713","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2018.5662\/2018","article-title":"Risk stratification and treatment of primary biliary cholangitis","volume":"111","author":"Mart\u00ednez J","year":"2019","unstructured":"Mart\u00ednez J, Aguilera L, Albillos A. Risk stratification and treatment of primary biliary cholangitis. Rev Esp Enferm Dig. 2019, 111:63-70. 10.17235\/reed.2018.5662\/2018","journal-title":"Rev Esp Enferm Dig"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.11.021","article-title":"Early molecular stratification of high-risk primary biliary cholangitis","volume":"14","author":"Hardie C","year":"2016","unstructured":"Hardie C, Green K, Jopson L, et al.. Early molecular stratification of high-risk primary biliary cholangitis. EBioMedicine. 2016, 14:65-73. 10.1016\/j.ebiom.2016.11.021","journal-title":"EBioMedicine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03163-y","article-title":"Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis","volume":"25","author":"Tian S","year":"2023","unstructured":"Tian S, Hu Y, Zhang M, et al.. Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis. Arthritis Res Ther. 2023, 25:186. 10.1186\/s13075-023-03163-y","journal-title":"Arthritis Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein AF","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020, 17:93-110. 10.1038\/s41575-019-0226-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot C","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al.. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018, 378:2171-81. 10.1056\/NEJMoa1714519","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2023.22239","article-title":"Management of primary biliary cholangitis: current treatment and future perspectives","volume":"34","author":"Barba Bernal R","year":"2023","unstructured":"Barba Bernal R, Ferrigno B, Medina Morales E, et al.. Management of primary biliary cholangitis: current treatment and future perspectives. Turk J Gastroenterol. 2023, 34:89-100. 10.5152\/tjg.2023.22239","journal-title":"Turk J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084321","article-title":"Exploring advanced therapies for primary biliary cholangitis: insights from the gut microbiota-bile acid-immunity network","volume":"25","author":"Guo Z","year":"2024","unstructured":"Guo Z, He K, Pang K, Yang D, Lyu C, Xu H, Wu D. Exploring advanced therapies for primary biliary cholangitis: insights from the gut microbiota-bile acid-immunity network. Int J Mol Sci. 2024, 25:4321. 10.3390\/ijms25084321","journal-title":"Int J Mol Sci"},{"key":"ref24","article-title":"A practical review of primary biliary cholangitis for the gastroenterologist","volume":"15","author":"Onofrio FQ","year":"2019","unstructured":"Onofrio FQ, Hirschfield GM, Gulamhusein AF. A practical review of primary biliary cholangitis for the gastroenterologist. Gastroenterol Hepatol (N Y). 2019, 15:145-54.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000551.pub3","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic JS","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012, 12:CD000551. 10.1002\/14651858.CD000551.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28140","article-title":"Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'","volume":"62","author":"Beuers U","year":"2015","unstructured":"Beuers U, Gershwin ME, Gish RG, et al.. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Hepatology. 2015, 62:1620-2. 10.1002\/hep.28140","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.818089","article-title":"Fibrates for the treatment of primary biliary cholangitis unresponsive to ursodeoxycholic acid: an exploratory study","volume":"12","author":"Can\u00e7ado GG","year":"2021","unstructured":"Can\u00e7ado GG, Couto CA, Guedes LV, et al.. Fibrates for the treatment of primary biliary cholangitis unresponsive to ursodeoxycholic acid: an exploratory study. Front Pharmacol. 2021, 12:818089. 10.3389\/fphar.2021.818089","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2130750","article-title":"Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)","volume":"31","author":"Wetten A","year":"2022","unstructured":"Wetten A, Jones DE, Dyson JK. Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC). Expert Opin Investig Drugs. 2022, 31:1101-7. 10.1080\/13543784.2022.2130750","journal-title":"Expert Opin Investig Drugs"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.744488","article-title":"Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury: a systematic review","volume":"12","author":"Robles-D\u00edaz M","year":"2021","unstructured":"Robles-D\u00edaz M, Nezic L, Vujic-Aleksic V, Bj\u00f6rnsson ES. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury: a systematic review. Front Pharmacol. 2021, 12:744488. 10.3389\/fphar.2021.744488","journal-title":"Front Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1184252","article-title":"Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?","volume":"14","author":"Yang Y","year":"2023","unstructured":"Yang Y, He X, Rojas M, Leung PS, Gao L. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?. Front Immunol. 2023, 14:1184252. 10.3389\/fimmu.2023.1184252","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/335864-breaking-grounds-a-comprehensive-analysis-of-cutting-edge-treatments-for-primary-biliary-cirrhosisprimary-biliary-cholangitis-with-futuristic-treatments","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T02:11:52Z","timestamp":1740449512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/335864-breaking-grounds-a-comprehensive-analysis-of-cutting-edge-treatments-for-primary-biliary-cirrhosisprimary-biliary-cholangitis-with-futuristic-treatments"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.79582","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}